89bio : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Form 8-K

89bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today... | March 24, 2022

Related Keywords

San Francisco ,California ,United States ,Herzliya ,Tel Aviv ,Israel ,Hank Mansbach ,Rohan Palekar ,Bryan Martins ,Development Rd Expenses ,Linkedin ,Nasdaq ,Teva Pharmaceuticals ,Reports Fourth Quarter ,Full Year ,Provides Corporate ,Chief Executive Officer ,Chief Medical Officer ,Annual Report ,Safe Harbor ,Private Securities Litigation Reform Act ,Consolidated Statement ,89bio ,Nc Stock Exchange ,News ,Information ,Press Release ,Iopharmaceutical ,Company ,Ocused ,N ,The ,Development ,End ,Ommercialization ,F ,Nnovative ,Therapies ,Or ,Treatment ,Liver ,Nd Etnb Us2825591033 ,